Impact of CYP2D6 on Venlafaxine Metabolism in Trinidadian Patients with Major Depressive Disorder

References

• Ramaswami R , VillarrealMD , PittaDM , CarpenterJS , StebbingJ , KalesanB . Venlafaxine in management of hot flashes in women with breast cancer: a systematic review and meta-analysis . Breast Cancer Res. Treat.152 ( 2 ), 231 – 237 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Aiyer R , BarkinRL , BhatiaA . Treatment of neuropathic pain with venlafaxine: a systematic review . Pain Med.18 ( 10 ), 1999 – 2012 ( 2017 ).
   PubMed Web of Science ®Google Scholar
• Aziz MT , GoodBL , LoweDK . Serotonin–norepinephrine reuptake inhibitors for the management of chemotherapy-induced peripheral neuropathy . Ann. Pharmacother.48 ( 5 ), 626 – 632 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Harvey AT , RudolphRL , PreskornSH . Evidence of the dual mechanisms of action of venlafaxine . Arch. Gen. Psychiatry57 ( 5 ), 503 – 509 ( 2000 ).
   PubMed Web of Science ®Google Scholar
• Klamerus KJ , MaloneyK , RudolphRL , SisenwineSF , JuskoWJ , ChiangST . Introduction of a composite parameter to the pharmacokinetics of venlafaxine and its active O-desmethyl metabolite . J. Clin. Pharmacol.32 ( 8 ), 716 – 724 ( 1992 ).
   PubMed Web of Science ®Google Scholar
• Muth E , MoyerJ , HaskinsJ , AndreeT , HusbandsG . Biochemical, neurophysiological, and behavioral effects of Wy-45,233 and other identified metabolites of the antidepressant venlafaxine . Drug Develop. Res.23 ( 2 ), 191 – 199 ( 1991 ).
   Web of Science ®Google Scholar
• Reneric JP , LuckiI . Antidepressant behavioral effects by dual inhibition of monoamine reuptake in the rat forced swimming test . Psychopharmacology136 ( 2 ), 190 – 197 ( 1998 ).
   PubMed Web of Science ®Google Scholar
• Sangkuhl K , StinglJC , TurpeinenM , AltmanRB , KleinTE . PharmGKB summary: venlafaxine pathway . Pharmacogenet. Genomics24 ( 1 ), 62 – 72 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Macaluso M , PreskornSH . CYP 2D6 PM status and antidepressant response to nortriptyline and venlafaxine: is it more than just drug metabolism?J. Clin. Psychopharmacol.31 ( 2 ), 143 – 145 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Nichols AI , FochtK , JiangQ , PreskornSH , KaneCP . Pharmacokinetics of venlafaxine extended release 75 mg and desvenlafaxine 50 mg in healthy CYP2D6 extensive and poor metabolizers: a randomized, open-label, two-period, parallel-group, crossover study . Clin. Drug Investig.31 ( 3 ), 155 – 167 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Nichols AI , LobelloK , Guico-PabiaCJ , PaulJ , PreskornSH . Venlafaxine metabolism as a marker of cytochrome P450 enzyme 2D6 metabolizer status . J. Clin. Psychopharmacol.29 ( 4 ), 383 – 386 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Preskorn S , PatronevaA , SilmanHet al. Comparison of the pharmacokinetics of venlafaxine extended release and desvenlafaxine in extensive and poor cytochrome P450 2D6 metabolizers . J. Clin. Psychopharmacol.29 ( 1 ), 39 – 43 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Caudle KE , DunnenbergerHM , FreimuthRRet al. Standardizing terms for clinical pharmacogenetic test results: consensus terms from the Clinical Pharmacogenetics Implementation Consortium (CPIC) . Genet. Med.19 ( 2 ), 215 – 223 ( 2017 ).
   PubMed Web of Science ®Google Scholar
• Shams ME , ArnethB , HiemkeCet al. CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine . J. Clin. Pharm. Ther.31 ( 5 ), 493 – 502 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Gaedigk A , SangkuhlK , Whirl-CarrilloM , KleinT , LeederJS . Prediction of CYP2D6 phenotype from genotype across world populations . Genet. Med.19 ( 1 ), 69 – 76 ( 2017 ).
   PubMed Web of Science ®Google Scholar
• Llerena A , DoradoP , Penas-LledoEM . Pharmacogenetics of debrisoquine and its use as a marker for CYP2D6 hydroxylation capacity . Pharmacogenomics10 ( 1 ), 17 – 28 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Llerena A , NaranjoME , Rodrigues-SoaresF , PenasLEM , FarinasH , Tarazona-SantosE . Interethnic variability of CYP2D6 alleles and of predicted and measured metabolic phenotypes across world populations . Expert Opin. Drug Metab. Toxicol.10 ( 11 ), 1569 – 1583 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Central Statistical Office. Population and Housing Census. Ministry of Planning and Sustainable Development, Republic of Trinidad and Tobago ( 2011 ). www.planning.gov.tt/ .
   Google Scholar
• Laurence KO . Immigration into the West Indies in the 19th Century . Caribbean Universities Press , London, UK ( 1971 ).
   Google Scholar
• Soares-Ramesar . Survivors of Another Crossing: A History of East Indians in Trinidad, 1880–1946. School of Continuing Studies . University of the West Indies , Trinidad and Tobago ( 1994 ).
   Google Scholar
• Montane Jaimé LK , LallaA , SteimerW , GaedigkA . Characterization of the CYP2D6 gene locus and metabolic activity in Indo- and Afro-Trinidadians: discovery of novel allelic variants . Pharmacogenomics14 ( 3 ), 261 – 276 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Mcalpine DE , BiernackaJM , MrazekDAet al. Effect of cytochrome P450 enzyme polymorphisms on pharmacokinetics of venlafaxine . Ther. Drug Monit.33 ( 1 ), 14 – 20 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Jornil J , NielsenTS , RosendalIet al. A poor metabolizer of both CYP2C19 and CYP2D6 identified by mechanistic pharmacokinetic simulation in a fatal drug poisoning case involving venlafaxine . Forensic Sci. Int.226 ( 1–3 ), e26 – e31 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Britzi M , BialerM , ArcaviL , ShachbariA , KapitulnikT , SobackS . Genetic polymorphism of CYP2D6 and CYP2C19 metabolism determined by phenotyping Israeli ethnic groups . Ther. Drug Monit.22 ( 5 ), 510 – 516 ( 2000 ).
   PubMed Web of Science ®Google Scholar
• Eap CB , LessardE , BaumannPet al. Role of CYP2D6 in the stereoselective disposition of venlafaxine in humans . Pharmacogenetics13 ( 1 ), 39 – 47 ( 2003 ).
   PubMedGoogle Scholar
• Sambrook J , FritschEF , ManiatisT . Molecular Cloning: A Laboratory Manual (Volume 1; 2nd Edition) . Cold Spring Harbor Laboratory Press , NY, USA ( 1989 ).
   Google Scholar
• Gaedigk A , SimonSD , PearceRE , BradfordLD , KennedyMJ , LeederJS . The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype . Clin. Pharmacol. Ther.83 ( 2 ), 234 – 242 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Bell GC , CaudleKE , Whirl-CarrilloMet al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 genotype and use of ondansetron and tropisetron . Clin. Pharmacol. Ther.102 ( 2 ), 213 – 218 ( 2017 ).
   PubMed Web of Science ®Google Scholar
• Crews KR , GaedigkA , DunnenbergerHMet al. Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update . Clin. Pharmacol. Ther.95 ( 4 ), 376 – 382 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Hicks JK , BishopJR , SangkuhlKet al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors . Clin. Pharmacol. Ther.98 ( 2 ), 127 – 134 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Hicks JK , SangkuhlK , SwenJJet al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update . Clin. Pharmacol. Ther. doi:10.1002/cpt.597 ( 2016 ) ( Epub ahead of print ).
   PubMed Web of Science ®Google Scholar
• Gaedigk A , Ingelman-SundbergM , MillerNAet al. The Pharmacogene Variation (PharmVar) Consortium: incorporation of the human cytochrome P450 (CYP) allele nomenclature database . Clin. Pharmacol. Ther. doi:10.1002/cpt.910 ( 2017 ) ( Epub ahead of print ).
   Web of Science ®Google Scholar
• Preskorn SH . Understanding outliers on the usual dose–response curve: venlafaxine as a way to phenotype patients in terms of their CYP 2D6 status and why it matters . J. Psychiatr. Pract.16 ( 1 ), 46 – 49 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Castanares-Zapatero D , GillardN , CapronA , HaufroidV , HantsonP . Reversible cardiac dysfunction after venlafaxine overdose and possible influence of genotype and metabolism . Forensic Sci. Int.266 , e48 – e51 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Lessard E , YessineMA , HamelinBA , O’HaraG , LeblancJ , TurgeonJ . Influence of CYP2D6 activity on the disposition and cardiovascular toxicity of the antidepressant agent venlafaxine in humans . Pharmacogenetics9 ( 4 ), 435 – 443 ( 1999 ).
   PubMedGoogle Scholar
• Cai WM , NikoloffDM , PanRMet al. CYP2D6 genetic variation in healthy adults and psychiatric African–American subjects: implications for clinical practice and genetic testing . Pharmacogenomics J.6 ( 5 ), 343 – 350 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Hertz DL , SnavelyAC , McLeodHLet al. In vivo assessment of the metabolic activity of CYP2D6 diplotypes and alleles . Br. J. Clin. Pharmacol.80 ( 5 ), 1122 – 1130 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Berm E , KokR , HakE , WilffertB . Relation between CYP2D6 genotype, phenotype and therapeutic drug concentrations among nortriptyline and venlafaxine users in old age psychiatry . Pharmacopsychiatry49 ( 5 ), 186 – 190 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Preskorn SH , KaneCP , LobelloKet al. Cytochrome P450 2D6 phenoconversion is common in patients being treated for depression: implications for personalized medicine . J. Clin. Psychiatry74 ( 6 ), 614 – 621 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Kalman LV , AgundezJ , AppellMLet al. Pharmacogenetic allele nomenclature: international workgroup recommendations for test result reporting . Clin. Pharmacol. Ther.99 ( 2 ), 172 – 185 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Shah RR , SmithRL . Addressing phenoconversion: the Achilles’ heel of personalized medicine . Br. J. Clin. Pharmacol.79 ( 2 ), 222 – 240 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Hicks JK , SwenJJ , GaedigkA . Challenges in CYP2D6 phenotype assignment from genotype data: a critical assessment and call for standardization . Curr. Drug Metab.15 ( 2 ), 218 – 232 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Wang D , PappAC , SunX . Functional characterization of CYP2D6 enhancer polymorphisms . Hum. Mol. Genet.24 ( 6 ), 1556 – 1562 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Wang D , PoiMJ , SunX , GaedigkA , LeederJS , SadeeW . Common CYP2D6 polymorphisms affecting alternative splicing and transcription: long-range haplotypes with two regulatory variants modulate CYP2D6 activity . Hum. Mol. Genet.23 ( 1 ), 268 – 278 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Gaedigk A . Complexities of CYP2D6 gene analysis and interpretation . Int. Rev. Psychiatry25 ( 5 ), 534 – 553 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Taranu A , ColleR , GressierFet al. Should a routine genotyping of CYP2D6 and CYP2C19 genetic polymorphisms be recommended to predict venlafaxine efficacy in depressed patients treated in psychiatric settings? Pharmacogenomics 18 ( 7 ), 639 – 650 ( 2017 ).
   PubMed Web of Science ®Google Scholar
• Cespedes-Garro C , NaranjoMG , Rodrigues-SoaresFet al. Pharmacogenetic research activity in Central America and the Caribbean: a systematic review . Pharmacogenomics17 ( 15 ), 1707 – 1724 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Koopmans AB , VinkersDJ , GelanPJ , HoekHW , Van HartenPN . CYP2D6 and CYP2C19 genotyping in psychiatric patients on psychotropic medication in the former Dutch Antilles . Pharmacogenomics18 ( 10 ), 1003 – 1012 ( 2017 ).
   PubMed Web of Science ®Google Scholar
• Naveen AT , AdithanC , SoyaSS , GerardN , KrishnamoorthyR . CYP2D6 genetic polymorphism in south Indian populations . Biol. Pharm. Bull.29 ( 8 ), 1655 – 1658 ( 2006 ).
   PubMed Web of Science ®Google Scholar